Indeed, a more recent study including 1540 patients with AML performed targeted sequencing of 111 genes and cytogenetic analysis and classified 11 subgroups,34 including ~18% of AML patients with mutations in chromatin modifiers (ASXL1, STAG2, BCOR, MLLPTD, EZH2, and PHF6) and spliceosome genes (SF3B1, SRSF2, U2AF1, and ZRSR2). The gene discussed is ASXL1; the disease is acute myeloid leukemia.